Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wiltberger, G; Matia, I; Schmelzle, M; Krenzien, F; Hau, HM; Freitas, B; Jonas, S; Fellmer, PT.
Mid- and long-term results after replacement of infected peripheral vascular prosthetic grafts with biosynthetic collagen prosthesis.
J Cardiovasc Surg (Torino). 2014; 55(5): 693-8.
Web of Science
PubMed
- Co-Autor*innen der Med Uni Graz
- Hau Hans-Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- AIM: We assess mid- and long-term outcome after prosthetic graft replacement with biosynthetic collagen prosthesis (Omniflow II®) in the presence of graft infection. METHODS: Between December 2010 and January 2012, an analysis of 9 consecutive patients was performed, who underwent replacement of an infected peripheral graft with a biosynthetic prosthesis. Morbidity, in-hospital mortality, primary and secondary patency were analyzed. FDG-PET was performed to diagnose graft infection, and exclude reinfection at long-term follow-up. RESULTS: Graft infection occurred after a median of 12 (range 3-97) months after the initial procedure. Replacement surgery was performed successfully in all 9 patients without intraoperative complications. Microbiological cultures revealed pathogenic infection in 7 cases. In 2 patients, no pathogen was isolated. The morbidity rate was 55.5% with no in-hospital deaths. Early and late bypass occlusion occurred in 2 patients. One high above-knee amputation was performed due to patient deterioration. The median length of stay was 23 (range 12-122) days and after graft replacement 13 (range 10-62) days. The median time of follow up was 23 (range 8-25) months. Primary and secondary patency rates were 66.6% and 78% at 19 months, respectively. FDG-PET was performed in 6 (85.5%) patients after a median follow up period of 19 (range 3-23) months, and excluded graft reinfection in all patients. CONCLUSION: Replacement of infected peripheral prosthetic grafts with the prosthesis (Omniflow II®) has encouraging results. The collagen prosthesis appears to be a promising alternative with a low reocclusion rate and no reinfection.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Amputation, Surgical - administration & dosage
- Blood Vessel Prosthesis - administration & dosage
- Blood Vessel Prosthesis Implantation - adverse effects, instrumentation, mortality
- Collagen - administration & dosage
- Device Removal - adverse effects, mortality
- Female - administration & dosage
- Graft Occlusion, Vascular - etiology, physiopathology, surgery
- Humans - administration & dosage
- Length of Stay - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prosthesis Design - administration & dosage
- Prosthesis-Related Infections - diagnosis, microbiology, mortality, physiopathology, surgery
- Recurrence - administration & dosage
- Reoperation - administration & dosage
- Risk Factors - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Vascular Patency - administration & dosage
- Find related publications in this database (Keywords)
- Infection
- Blood vessel prosthesis
- Vascular surgical procedures